阅读说明：本技术 一种用于辅助治疗肠道疾病的固体饮料及其制备方法与应用 (Solid beverage for adjuvant therapy of intestinal diseases and preparation method and application thereof ) 是由 姚青 候宁 汪家琦 于 2020-05-28 设计创作，主要内容包括：本发明公开了一种用于辅助治疗肠道疾病的固体饮料及其制备方法与应用,所述固体饮料的制备原料包括：骆驼奶粉、羊奶粉、水苏糖、燕麦粉、圆苞车前子壳粉、淡竹叶粉、昆布粉和复合益生菌；其中,所述复合益生菌包括植物乳杆菌、嗜热链球菌、两歧双杆菌、梭状芽孢杆菌和乳酸乳杆菌。骆驼奶可抑制体内不饱和醛酮对肠道平滑肌的破坏,促使肠蠕动的功能修复,同时,还能使得肠道内的有益菌快速繁殖,形成强大的有益菌群,以抑制肠道有害菌,营造健康的肠内微生物环境；骆驼奶、水苏糖和复合益生菌等间可相互协同配合降低促炎性细胞因子IFN-γ分泌,改善结肠组织损伤和免疫保护作用。(The invention discloses a solid beverage for adjuvant therapy of intestinal diseases and a preparation method and application thereof, wherein the solid beverage comprises the following raw materials: camel milk powder, goat milk powder, stachyose, oat powder, Plantago ovata shell powder, phyllostachys pubescens leaf powder, thallus laminariae powder and composite probiotics; wherein the composite probiotics comprise lactobacillus plantarum, streptococcus thermophilus, bifidobacterium bifidum, clostridium and lactobacillus lactis. The camel milk can inhibit the damage of unsaturated aldehyde ketone in vivo to the smooth muscle of the intestinal tract, promote the functional repair of intestinal peristalsis, and simultaneously, can also enable beneficial bacteria in the intestinal tract to rapidly propagate to form a strong beneficial bacteria group so as to inhibit harmful bacteria in the intestinal tract and build a healthy intestinal microbial environment; camel milk, stachyose and composite probiotics can cooperate with each other to reduce the secretion of proinflammatory cytokine IFN-gamma and improve the damage of colon tissues and the immune protection effect.)

1. A solid beverage for auxiliary treatment of intestinal diseases is characterized in that: the preparation raw materials of the solid beverage comprise: camel milk powder, goat milk powder, stachyose, oat powder, Plantago ovata shell powder, phyllostachys pubescens leaf powder, thallus laminariae powder and composite probiotics;

wherein the composite probiotics comprise lactobacillus plantarum, streptococcus thermophilus, bifidobacterium bifidum, clostridium and lactobacillus lactis.

2. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the preparation raw materials also comprise flavoring agents, and the flavoring agents comprise lemon powder, strawberry powder, orange powder and green plum powder; preferably, the mass ratio of the lemon powder, the strawberry powder, the fragrant orange powder and the green plum powder is (2-3): 1-5): 2-4): 1-3.

3. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the weight ratio of camel milk powder, sheep milk powder, stachyose, oat powder, Plantago ovata shell powder, phyllostachys edulis powder, thallus laminariae powder and composite probiotics is (40-50): 30-35): 2-5): 2-8): 1-5): 1-8): 5-10.

4. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the mass ratio of the lactobacillus plantarum to the streptococcus thermophilus to the bifidobacterium bifidum to the clostridium and the lactobacillus lactis is (2-4) to (2-5) to (2-4) to (1-4) to (3-5).

5. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the number of viable bacteria in the composite probiotics is not less than 10⁹CFU/g。

6. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the preparation method of the stachyose comprises the following steps:

adding cordyceps sinensis and ginseng into water with the temperature of 50-80 ℃, ultrasonically leaching for 1-2 hours, and squeezing to obtain a crude extract;

adding yeast into the crude extract for fermentation to obtain fermentation liquor;

adding quicklime into the fermentation liquor until the fermentation liquor is saturated, heating to 50-55 ℃, and introducing carbon dioxide to generate calcium carbonate precipitate;

filtering, collecting filtrate, purifying, concentrating, and drying to obtain stachyose.

7. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 6, characterized in that: and during ultrasonic leaching, the ultrasonic power is 200-300W.

8. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 6, characterized in that: the purification operation comprises the following steps: performing high-pressure preparative liquid chromatography on the filtrate by using an aminopropyl bonded silica gel column, taking acetonitrile-water as an eluent, performing constant-current elution for at least 50min at a speed of 50-150 ml/min, and collecting liquid in a stachyose peak-off time period; preferably, the volume ratio of acetonitrile to water in the eluent is 75-80: 20-25.

9. The method for preparing a solid beverage for the adjuvant treatment of intestinal diseases according to any one of claims 1 to 8, wherein: the method comprises the following steps:

mixing the above materials by equivalent incremental mixing method, and mixing.

10. Use of the solid beverage according to any one of claims 1 to 8 for the preparation of a solid beverage for the adjuvant treatment of intestinal disorders.

Technical Field

The invention relates to the technical field of functional foods, in particular to a solid beverage for adjuvant therapy of intestinal diseases and a preparation method and application thereof.

Background

The intestinal tract is an important digestive organ of a human body and also a maximum immune and toxin expelling organ of the human body, and has a great influence on the health of the human body. More than 80% of health problems in humans are caused by the intestinal tract, such as: constipation, diarrhea, halitosis, pachylosis, mottle, belly, hypertension, hyperlipidemia, gastroenteritis, etc., because when the intestinal tract fails to operate normally, the toxins in the body are discharged out of the body through other ducts (kidney, skin, respiration). Therefore, the improvement of the intestinal health has important significance on the human health.

The enhancement of the intestinal immune system is an important way for assisting in treating intestinal diseases and improving intestinal health, and the intestinal immune system consists of intestinal related lymphoid tissues, intestinal mucosal immune cells, immune media and the like and is also an important component of the body immune system. The intestinal mucosal immune cells typically exhibit immune tolerance to the normal microbiota and food antigens in the gut, while evoking an immune response to pathogenic microorganisms, producing an immune response. Cytokines are small molecular proteins with a wide range of biological activities synthesized and secreted by immune cells (such as monocytes, macrophages, T cells, B cells, NK cells, etc.) and certain non-immune cells (endothelial cells, epidermal cells, fibroblasts, etc.), and have important roles in immune responses of the body, and have various biological functions, such as regulation of cell growth, differentiation maturation, functional maintenance, regulation of immune responses, participation in inflammatory reactions, wound healing, tumor growth, and the like. Relevant researches show that the initiation of the intestinal inflammation and the chronization of the intestinal inflammation are largely related to the imbalance of proinflammatory cytokines and anti-inflammatory cytokines, and once the balance of the proinflammatory cytokines and the anti-inflammatory cytokines is broken, immune cells can also cause immune response to normal flora and food antigens, so that inflammatory reaction is generated. Therefore, regulation of gut cytokines to maintain a balance between pro-inflammatory and anti-inflammatory cytokines is of great importance to enhance the gut immune system.

The functional food is food with specific nutrition and health care functions, and more research results show that the functional food exerts the functional characteristics by influencing the human health through the cytokine network of the organism. Therefore, if a functional food capable of regulating and controlling body cytokines can be developed, the functional food has important significance for the adjuvant therapy of intestinal diseases.

Disclosure of Invention

The present invention is directed to solving at least one of the problems of the prior art. Therefore, the invention provides the solid beverage which can be used for assisting in treating intestinal diseases by regulating and controlling the level of the intestinal cell factors.

The invention also provides a preparation method of the solid beverage.

The invention also provides application of the solid beverage.

According to the first aspect of the invention, the solid beverage is prepared from the raw materials comprising: camel milk powder, goat milk powder, stachyose, oat powder, Plantago ovata shell powder, phyllostachys pubescens leaf powder, thallus laminariae powder and composite probiotics;

wherein the composite probiotics comprise lactobacillus plantarum, streptococcus thermophilus, bifidobacterium bifidum, clostridium and lactobacillus lactis.

The solid beverage according to the embodiment of the invention has at least the following beneficial effects: the camel milk can inhibit the damage of unsaturated aldehyde ketone in vivo to the smooth muscle of the intestinal tract, promote the functional repair of intestinal peristalsis, and simultaneously, can also enable beneficial bacteria in the intestinal tract to rapidly propagate to form a strong beneficial bacteria group so as to inhibit harmful bacteria in the intestinal tract and build a healthy intestinal microbial environment; stachyose has obvious proliferation effect on beneficial bacteria such as bifidobacterium, lactobacillus and the like in intestinal tract, can quickly improve the environment in the digestive tract of a human body, regulate the balance of microbial flora, adsorb toxic substances and pathogenic bacteria in the gastrointestinal tract, improve the disease resistance of the body and enhance the immunity; in the composite probiotics, the bifidobacterium bifidum and the lactobacillus can inhibit the proliferation of Th2 type cells and promote the proliferation of Th1 type cells, the Th1 type cells can inhibit the proliferation of Th2 type cells, and the Th2 cells can inhibit the secretion of IFN-gamma by the Th1 type cells; therefore, camel milk, stachyose, composite probiotics and the like can cooperate with each other to reduce the secretion of proinflammatory cytokine IFN-gamma, and improve the damage of colon tissues and the immune protection effect. Meanwhile, the short-chain fatty acid, Plantago ovata husk and dietary fiber substances contained in oat flour which are rich in the goat milk powder are fermented and decomposed by lactobacillus plantarum, streptococcus thermophilus and the like to generate the short-chain fatty acid and polysaccharide components contained in lophatherum gracile and kelp, so that the intestinal epithelial barrier function and the immune tolerance can be synergistically enhanced, the intestinal homeostasis is promoted, an inflammasome is activated, and then interleukins (such as IL-18, IL-12, IL13 and the like) are generated, the secretion of IgA is increased through B cells, the expression of T cell activating molecules in antigen presenting cells is reduced, and the number and the function of regulatory T cells (including anti-inflammatory cytokines such as transforming growth factor-beta, IL-10 and the like) are increased.

According to some embodiments of the invention, the preparation raw materials further comprise a flavoring agent, the flavoring agent comprising lemon powder, strawberry powder, orange powder, and green plum powder; preferably, the mass ratio of the lemon powder, the strawberry powder, the fragrant orange powder and the green plum powder is (2-3): 1-5): 2-4): 1-3. The flavoring agent is compounded by a plurality of fruit powders, so that the taste is adjusted, and meanwhile, the vitamin can be supplemented, and the immunity of the organism is further improved and enhanced.

According to some embodiments of the present invention, the weight ratio of camel milk powder, goat milk powder, stachyose, oat powder, psyllium husk powder, phyllostachys edulis leaf powder, laminaria powder and composite probiotics is (40-50): 30-35): 2-5): 2-8): 1-5): 1-8): 5-10.

According to some embodiments of the invention, the mass ratio of Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium bifidum, Clostridium and Lactobacillus lactis is (2-4): 2-5: (2-4): 1-4: 3-5.

According to some embodiments of the invention, the number of viable bacteria in the composite probiotic is not less than 10⁹CFU/g。

According to some embodiments of the invention, the stachyose is prepared by the following steps:

adding cordyceps sinensis and ginseng into water with the temperature of 50-80 ℃, ultrasonically leaching for 1-2 hours, and squeezing to obtain a crude extract;

adding yeast into the crude extract for fermentation to obtain fermentation liquor;

adding quicklime into the fermentation liquor until the fermentation liquor is saturated, heating to 50-55 ℃, and introducing carbon dioxide to generate calcium carbonate precipitate;

filtering, collecting filtrate, purifying, concentrating, and drying to obtain stachyose.

According to some embodiments of the invention, the ultrasonic power of the ultrasonic leaching is 200-300W.

According to some embodiments of the invention, the conditions during the fermentation are: the pH value of the reaction system is between 4 and 5, and the fermentation is carried out for 20 to 30 hours at the temperature of between 35 and 38 ℃ in a ventilating way.

According to some embodiments of the invention, the filtration is ultrafiltration.

According to some embodiments of the invention, the purifying is performed by: and (3) performing high-pressure liquid chromatography on the filtrate by using an aminopropyl bonded silica gel column, using acetonitrile-water as an eluent, performing constant-current elution for at least 50min at a speed of 50-150 ml/min, and collecting liquid in a stachyose peak-off time period.

According to some embodiments of the invention, the volume ratio of acetonitrile to water in the eluent is 75-80: 20-25. Stachyose can be better eluted at the elution ratio, and higher yield (more than 90%) is obtained.

According to some embodiments of the invention, the high pressure is 20 to 40 bar.

According to some embodiments of the invention, the concentrating and drying operation is: and (3) carrying out vacuum concentration at the vacuum degree of 0.08-0.1 MPa and the temperature of 50-70 ℃, and freeze-drying the concentrated solution to obtain the stachyose.

A method of making an embodiment according to the second aspect of the invention comprises the steps of:

mixing the above materials by equivalent incremental mixing method, and mixing.

The preparation method according to the embodiment of the invention has at least the following beneficial effects: the preparation method of the scheme of the invention is simple to operate, and the equal incremental mixing method is adopted, so that the mixing effect is better.

According to the application of the embodiment of the third aspect of the invention, the solid beverage is used for preparing the solid beverage for assisting in treating intestinal diseases.

Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.

Detailed Description

In order to explain the technical content, the objects and the effects of the present invention in detail, the following description will be given with reference to the embodiments. The test methods used in the examples are all conventional methods unless otherwise specified; the materials, reagents and the like used are commercially available reagents and materials unless otherwise specified.

The embodiment of the invention is as follows: a solid beverage for auxiliary treatment of intestinal diseases is prepared from the following raw materials: camel milk powder, goat milk powder, stachyose, oat powder, plantain seed shell powder, phyllostachys pubescens leaf powder, laminaria powder and composite probiotics, wherein the weight parts are shown in the following table 1:

TABLE 1

Wherein the composite probiotics comprise lactobacillus plantarum, streptococcus thermophilus, bifidobacterium bifidum, clostridium and lactobacillus lactis, and the mass ratio of the lactobacillus plantarum to the streptococcus thermophilus is 3: 3:4:2:4, viable count 8 x 10⁹CFU/g or so.

And (3) designing a clinical test:

the test population: the test product is suitable for patients with intestinal diseases, the age of the test subject is 25-45 years, the test subject does not have other diseases, the test subject does not take medicines related to the tested functions in a short period, and the test subject is not allergic to the test product.

Grouping tests: according to the intestinal condition and age, 400 subjects were randomly divided into 8 groups of 50 persons each, of which example 4 group, control group 3 group, and blank control group 1 group (with an equal amount of placebo).

The eating method comprises the following steps: the test dose of 8 groups is the same, and the test dose is 2 times per day, 1.5g each time, and the test dose is continuously taken for 30 days.

The results of the clinical trials are detailed in table 2.

TABLE 2

As can be seen from table 2, compared with the blank control group, the test group taking the functional probiotic solid beverage provided by the embodiment of the invention has significant effects of maintaining intestinal health and improving immunity. Compared with the data of the comparative examples, the data of the comparative examples are that the improvement effect of the comparative examples on the intestinal diseases is not obvious, the comparative examples have better effects, the effect can be quickly achieved, the IgA content can be obviously increased, and the IFN-gamma content can be reduced, wherein the effect of the comparative example 3 is the best. The dosage of the components of the invention is shown to be within the weight part range limited by the invention, so as to achieve the effects of maintaining the intestinal health and improving the immunity.

The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all equivalent modifications made by the present invention in the specification or directly or indirectly applied to the related technical field are included in the scope of the present invention.